Alza Corporation

Durect Corporation

James Matriano

Peter E Daddona

Michel J N Cormier

Richard L Keenan

Joseph Creagan Trautman

WeiQi Lin

Ahmad P Samiee

Felix T Theeuwes

Su Il Yum

John W Gibson

Keith Edward Branham

William W Van Osdol

Michael M Sekar

John Tipton

Whitney Moro

Michel J Cormier

Juanita A Johnson

Wei Qi Lin

The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.

Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same

A method and device are described for applying a microprotrusion member () including a plurality of microprotrusions () to the stratum corneum with impact. The method and device are used to improve transport of an agent across the skin for agent delivery or sampling. The applicator () causes the microprotrusion member () to impact the stratum corneum with a certain amount of impact determined to effectively pierce the skin with the microprotrusions (). The preferred applicator () impacts the stratum corneum with the microprotrusion member () with an impact of at least 0.05 joules per cmof the microprotrusion member () in 10 msec or less.

Apparatus and method for piercing skin with microprotrusions

This invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes. The desired result is achieved by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).

Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure

A minimally invasive transdermal nucleic acid sampling method comprises piercing through the outermost layer of the skin and into the underlying epidermis with a plurality of microprojections. Living skin cells in the underlying epidermis are disrupted, causing them to release their contents including their nucleic acids (i.e., DNA, RNA, fragments thereof or other polynucleic acid material found in the nucleii and/or mitochondria of cells). The nucleic acid is collected on the surfaces of the microprojections and/or in a separate nucleic acid collection reservoir. The collected nucleic acid is then analyzed using standard polymerase chain reaction (PCR) techniques. Optionally a suction device applies a partial vacuum through openings in the microprojection member to the microcuts in the skin for enhanced efflux of intracellular and extracellular (i.e., body) fluids containing the nucleic acid.

Method for transdermal nucleic acid sampling

Growing community of inventors

Mountain View, CA, United States of America

James Matriano